Retatrutide in Australia: a triple-agonist research guide

Retatrutide in Australia. Retatrutide (LY3437943) is a synthetic peptide studied in published research as a single-peptide triple agonist of the GLP-1, GIP and glucagon receptors — three class-B G-protein-coupled receptors whose signalling converges in metabolic and energy-homeostasis research. This guide is a research-reference summary for Australian researchers, framed strictly around receptor pharmacology. It makes no medical, therapeutic, weight-loss, or body-composition claim.

The triple-agonist receptor profile

Retatrutide is a 39-residue synthetic peptide whose backbone carries non-standard residues (aminoisobutyric-acid substitutions and an α-methyl-leucine that resist enzymatic degradation) plus a C20 fatty-diacid conjugate that supports albumin binding. In receptor research it is characterised as a balanced triple agonist of the GLP-1, GIP and glucagon receptors — the addition of glucagon-receptor activity is what distinguishes it from dual incretin agonists in the literature.

What the published research reports

The discovery and receptor-pharmacology profile of this single-peptide triple agonist were reported by Coskun and colleagues (Cell Metabolism, 2022), who characterised its balanced glucagon- and GLP-1-receptor activity alongside greater GIP-receptor activity. The first-in-human pharmacokinetic work — the profile behind the extended half-life that supports once-weekly research dosing schedules — was reported by Urva and colleagues (The Lancet, 2022). Elite AU Peptides cites these as published research findings only; the material supplied here is a research-grade peptide, not a medicine.

Retatrutide in context

Retatrutide extends the multi-agonist concept beyond tirzepatide (an approved GLP-1 / GIP dual agonist) by adding glucagon-receptor activity on the same peptide backbone, which is why it is frequently compared with tirzepatide in receptor-pharmacology research — see the retatrutide vs tirzepatide comparison. Within the catalogue it sits alongside tesamorelin (a GHRH-analogue) — the retatrutide vs tesamorelin comparison and the GLP-1 research peptides pillar cover the wider incretin-research space.

Identity, purity and compliance

Retatrutide is stocked in 10mg, 15mg, 20mg and 30mg lyophilised vials, each batch independently HPLC-tested by Janoshik before listing, with the certificate published on the product page and in the lab-reports library. Retatrutide is an investigational compound in published research; the material here is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption. Elite AU Peptides makes no medical, therapeutic, weight-loss, or body-composition claim; anything above is a research-reference summary, not medical advice.